DNAJC16 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human ovarian carcinoma cell line A2780. This product provides a loss-of-function model for DNAJC16, a co-chaperone of the DNAJ/HSP40 family, enabling investigation of its role in protein folding and cellular stress responses. The polyclonal pool comprises a heterogeneous mixture of edited cells without clonal selection, suitable for studying population-level phenotypes.
The A2780 cell line is an adherent epithelial line isolated from an untreated patient with ovarian endometrioid adenocarcinoma. It serves as a well-characterized model for ovarian cancer research, particularly in drug response and resistance studies, and retains relevant signaling pathways, including stress response networks.
DNAJC16 functions as an HSP40 co-chaperone that partners with HSP70 family members (e.g., HSPA1A, HSPA8) to facilitate protein folding and degradation. It is integral to the unfolded protein response (UPR) and ER-associated degradation (ERAD), helping maintain proteostasis. Its expression is regulated by heat shock factor 1 (HSF1) and induced by ER stress inducers (tunicamycin, thapsigargin) and cellular stressors (hypoxia, nutrient deprivation). Through HSP70, DNAJC16 influences client protein stability, potentially modulating AKT and ERK signaling. It interacts with co-chaperones BAG3, HIP, and HOP, and its loss impacts UPR sensors IRE1, PERK, and ATF6, altering downstream effectors GRP78 and CHOP.
Disruption of DNAJC16 in A2780 cells is expected to impair HSP70-mediated proteostasis, causing misfolded protein accumulation and elevated ER stress. This may dysregulate UPR signaling via IRE1, PERK, and ATF6, increasing GRP78 and CHOP expression. Given the dependence of cancer cells on proteostasis, this knockout model enables dissection of co-chaperone roles in ovarian cancer survival and stress adaptation. It can be used to test how DNAJC16 loss affects sensitivity to proteotoxic agents like cisplatin and proteasome inhibitors, which are central to ovarian cancer treatment.
This polyclonal knockout cell product supports diverse applications: western blotting for HSP70, CHOP, and GRP78; RT-qPCR for UPR targets; co-immunoprecipitation of the DNAJC16?CHSP70 complex; and drug response profiling via MTS/MTT and annexin V/PI assays. Immunofluorescence detects ER stress markers, while functional genomics can identify synthetic lethalities within the DNAJ family. These cells provide a versatile platform for ovarian cancer proteostasis research. For further details, please contact Ascent Research.
